Status:
NOT_YET_RECRUITING
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Endometrial Neoplasms
TP53 Gene Mutation
Eligibility:
FEMALE
18+ years
Brief Summary
The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor...
Detailed Description
The test is sequenced using Illumina high-throughput sequencers and accompanying kits. Conduct preliminary quality control on the samples, and the tumor cell content of the tissue samples shall not be...
Eligibility Criteria
Inclusion
- willing to participate in the study and sign the informed consent
- age ≥18 years old
- researchers evaluated that it was suitable to participate in this translational study
- Endometrial cancer was confirmed histologically
- histopathological molecular classification was consistent with pMMR type and POLE wild type
- The tumor tissue obtained by operation was the primary lesion
Exclusion
- Received chemotherapy within 14 days prior to sample collection, or received anti-tumor drug therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, within 21 days prior to sample collection
- previously treated with KIF18A inhibitors
- researchers believed that the subjects were not suitable for the translational study for other reasons
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06521684
Start Date
September 1 2024
End Date
June 1 2025
Last Update
July 26 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.